Tobacco and Vapes Bill (Twelfth sitting)

Debate between Sadik Al-Hassan and Andrew Gwynne

Committee stage
Thursday 23rd January 2025 Public Bill Committees

[Andrew Gwynne]

As I said to my hon. Friend the Member for Cardiff West, we will take all this away and look at it in detail, and we will come back to Members. I am just about legally savvy enough to understand the point that the hon. Lady is making that a break clause or something like it would probably be required, because the coming into law of the Tobacco and Vapes Bill on Royal Assent is expected—it is not an act of God, and it will not come as a complete shock and surprise.

Finally, clause 133 allows us to extend all of part 6 to cover devices that enable a

“tobacco product to be consumed”

or

“an item which is intended to form part of such a device”,

but that are not in the Bill.

[Sadik Al-Hassan (North Somerset) (Lab)]

On the conversation we were having previously, does the reference in clause 125(3) to a “specified date” mean that we can have an open discussion with the Secretary of State in the next stage of the Bill’s passage about deciding at what point the provision will apply to the contracts?

[Andrew Gwynne]

I will take that away, because I do not know the answer off the top of my head. In bringing forward regulations, the Secretary of State and I will want to ensure that we get these measures right. That is why there are statutory duties to consult on secondary legislation throughout the Bill. That will ensure that we get these measures and the details right, and that there will hopefully be no ambiguity about the different dates for the offences of printing, publishing and distributing advertisements or about those related to sponsorship deals and the production of the kits that come out of them. With that, I commend the clauses to the Committee.

Question put and agreed to.

Clause 124 accordingly ordered to stand part of the Bill.

Clause 125 ordered to stand part of the Bill.

Ordered, That further consideration be now adjourned. —(Taiwo Owatemi.)

Tobacco and Vapes Bill (First sitting)

Debate between Sadik Al-Hassan and Andrew Gwynne

Committee stage
Tuesday 7th January 2025 Public Bill Committees

[Andrew Gwynne]

Q In a nutshell, how important is it that the measures in the Bill are passed?

Dr Ian Walker: Critical. Without a doubt, there is no single bigger action that you could take to reduce the cancer burden on the country. The cancer burden sits at a very personal, individual level for people getting their own diagnosis; it sits at a family level and at a friend level. It also sits at an economic level for the country and at an NHS level, in terms of the burden that smoking-related illnesses cause for the NHS.

From my perspective, this is a world-leading piece of legislation. It is absolutely an opportunity for generational change and a long-term legacy that will see our children and grandchildren never able to legally buy tobacco in the UK and never exposed to the harms that that would cause them.

[Sadik Al-Hassan]

Q Is there any research into passive vaping risks to bystanders, who do not have a choice if someone is vaping next to them?

Sarah Sleet: As I said earlier, the research evidence around vaping harms is currently very poor. There has not been enough. It takes a long time to build up evidence of things that are generally very progressive rather than having an immediate impact, so we will have to wait. We need to put that in place, and we are going to have to wait to get that evidence back.

We have had anecdotal reports from our beneficiaries and those who contact the organisation about places—particularly in closed spaces, but sometimes outside—where there is a concentration of vaping. It is that classic thing where you go through a door and suddenly everybody around you is vaping immediately outside it. We get reports that that exacerbates people’s asthma and sometimes their COPD, but they are anecdotal. We really need the evidence base to support what is happening.

Dr Ian Walker: The only thing that I would add specifically from a cancer perspective is that although there is very little long-term evidence, because the products have not been around long enough and the cumulative effects have not been seen yet, what we do know, based on the current evidence, is that vapes are far less harmful than cigarettes. You heard the advice earlier that if you smoke it is better to vape or take other nicotine products, but if you do not smoke you should not vape, because we do not know yet what the long-term effects will be. In particular, we are very light on evidence on what the impact of vaping will be on bystanders.

Tobacco and Vapes Bill (Second sitting)

Debate between Sadik Al-Hassan and Andrew Gwynne

Committee stage
Tuesday 7th January 2025 Public Bill Committees

[Andrew Gwynne]

Q I can assure you that there will be consultation with the sector. What would you want to see from a licensing scheme? Are there any lessons from supporting the implementation of alcohol licensing, for example?

Inga Becker-Hansen: We would like to see a licensing scheme as a level playing field where small, independent and larger retailers are viewed on the same level. Again, we would encourage the multi-stores to require only one licence rather than looking at individual premises licences, because that will make things more difficult.

In terms of the tobacco scheme, ideally things would be grouped together so that there is less administrative burden and therefore less cost for retailers, so that, if the aim for the Government is to transfer from the idea of selling tobacco to people to selling vapes because of the health benefits, that transition is made easier for retailers. Adding on an additional licensing scheme with additional costs and a separate administrative system makes it more difficult for retailers to handle those things at the same time, particularly smaller retailers and independents.

[Sadik Al-Hassan]

Q We talked a little bit about the new licensing scheme’s impact on retailers, and you have talked about a level playing field. You say that large companies should have one licence across multiple branches. How does that balance the risk that these measures will disproportionately impact small and independent retailers, which will have to apply for a licence for every individual premises?

Inga Becker-Hansen: It is a bit difficult for me to give you specific details, but in initial response my thinking would be that it would be a discussion between retailers and their primary authority and how that is handled, bearing in mind smaller retailers versus larger retailers. I am happy to follow up in writing and give evidence that way, but I cannot give specific details currently.